Right to Life Australia
The President of Right to Life Australia, Margaret Tighe, condemned in the strongest terms the actions of those members of the Tasmanian Parliament, who voted in favour of the Gaffney euthanasia bill.
This was in the face of the advice Australia wide of the overwhelming majority of Australian doctors – especially medical oncologists and palliative care specialists.
“Frankly,” she said, “the descendants of my late mother’s convict ancestors would have ultimately been better off in the UK, whose House of Commons in 2015 overwhelmingly voted against legalising euthanasia or physician assisted suicide.”
/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length.
HACKENSACK, NJ / ACCESSWIRE / March 5, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology
BRCA-related cancers alone (
P=0.008); and those who showed sensitivity to platinum-based chemotherapy, at 4.1 months versus 2.2 months in patients with platinum-resistant disease (
P=0.01). The findings suggest that the PARP inhibitor olaparib may have therapeutic value for patients with platinum-sensitive PDAC [pancreatic ductal adenocarcinoma] with specific DDR-GAs other than germline
BRCA variants, the authors concluded.
OS reached 13.6 months in the DDR-GA group (95% CI 9.69-not reached) and was significantly longer for patients with platinum-sensitive versus platinum-resistant disease (10.5 vs 5.4 months,
P=0.03).
The phase III POLO study showed that PARP inhibition with olaparib as maintenance therapy improved PFS versus placebo in advanced pancreatic cancer patients with germline
Due to new medications in discovery, the outcomes for patients with cancer are increasingly improving; however, the cost of this improved care is also increasing.